ArticleCytotechnology2024
Hydrolyzed cow colostrum extract (BCFM) inhibits alpha-MSH-induced melanogenesis in B16F1 cells via regulation of the MC1R-cAMP signaling pathway.
Article in Cytotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Potential of Encapsulated Bovine Colostrum in Powder-Based Formulations for Facial Clay, Peel-Off Gel, and Sleeping Gel Masks.Gels (Basel, Switzerland) · 2025Article
- Research progress on peptides that inhibit melanin synthesis.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cow colostrum is the first milk produced after birth and is a rich natural source of nutrients, immunoglobulins, peptides, and growth factors. The bioconversion of milk and whey changes the immobilization and biochemical characterization. However, the cellular mechanism and the anti-melanin synthesis effects of hydrolyzed cow colostrum extract (BCFM) in alpha-MSH-induced B16F1 cells have not been examined. In this study, we investigated the anti-melanogenesis mechanism by examining the effects of BCFM in alpha-MSH-induced B16F1 cells. Cells were treated with BCFM in the presence or absence of alpha-MSH and co-cultured for 24, 48, and 72 h. The treatment of B16F1 cells with alpha-MSH resulted in the darkening of the color of the cells and induction of melanin synthesis. In addition, the expression levels of MC1R and cAMP, as well as phosphorylation levels of CREB and PKA, were increased by alpha-MSH treatment. However, concomitant treatment with BCFM resulted in a significant decrease in these factors and phosphorylated MITF. At the same time, the expressive amount of TRP-1 and tyrosinase was also decreased in B16F1 cells. These results demonstrate the potential of BCFM for the prevention of melanogenesis progression via the regulation of the MC1R-cAMP signaling pathway in alpha-MSH-induced B16F1 cells. The administration of BCFM suppressed the expression of TRP-1 and/or tyrosinase by regulating the CREB/MITF signaling pathways in the B16F1 cells. We propose that hydrolyzed cow colostrum extract (BCFM) is suitable for use as a novel active agent for skin whitening or pharmaceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.